- FibroGen licenses anemia compounds to Astellas
- FibroGen licenses anemia candidate to Yamanouchi
- Bayer HealthCare to sell Nuvelo's blood clotting agent; ends
- Yamanouchi buys Fujisawa for $7.64bn
- Astellas licenses Theravance gram-positive antibiotic; deal terminated
- Basilea signs antibiotic deal with J&J; terminated
- Astellas Pharma buys Biogen Idec's Amevive for $60mm
- Takeda licenses Affymax's Hematide for Japan; deal ends
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.